AZN (AstraZeneca) Ending Cash Position : $5,207 Mil (As of Mar. 2025)

View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Ending Cash Position?

AstraZeneca's Ending Cash Position for the quarter that ended in Mar. 2025 was $5,207 Mil.

AstraZeneca's quarterly Ending Cash Position increased from Sep. 2024 ($4,435 Mil) to Dec. 2024 ($5,429 Mil) but then declined from Dec. 2024 ($5,429 Mil) to Mar. 2025 ($5,207 Mil).

AstraZeneca's annual Ending Cash Position declined from Dec. 2022 ($5,983 Mil) to Dec. 2023 ($5,637 Mil) and declined from Dec. 2023 ($5,637 Mil) to Dec. 2024 ($5,429 Mil).

AstraZeneca Ending Cash Position Historical Data

The historical data trend for AstraZeneca's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Ending Cash Position Chart

AstraZeneca Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

7,546.00

6,038.00

5,983.00

5,637.00

5,429.00

AstraZeneca Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															7,692.00	6,677.00	4,435.00	5,429.00	5,207.00

AstraZeneca Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

AstraZeneca's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	5637	+	-208
	=	5,429

AstraZeneca's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	5429	+	-222
	=	5,207

AstraZeneca Ending Cash Position Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil AZNA:Austria AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.